0210 Notch series A
BioCentury & Getty Images

Emerging Company Profile

Notch’s $85M series A builds on Allogene deal for off-the-shelf, iPSC-derived cell therapies

Emerging Company Profile: Notch’s manufacturing leap could bring scale

Notch’s iPSC differentiation platform could enable the company to manufacture cell therapies at scale. 

Feb 10, 2021 | 9:34 PM GMT

Building on an early partnership with Allogene in blood cancers, Canadian start-up Notch has raised $85 million in a series A round designed to bring the

Read the full 740 word article

How to gain access

Continue reading with a
two-week free trial.